Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEG-rhG-CSF for Chemotherapy-induced Neutropenia in Breast Cancer
NCT02761460Phase 3Unknown
- Start
- May 2016
- Primary completion
- Apr 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of pegfilgrastim in neutropenia. Primary endpoint: The rate of III or IV class of neutropenia at 1 year. Status: unknown.
02
Drugs
pegfilgrastim
03
Conditions
neutropenia
Beyond the preview
Go deeper on NCT02761460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02761460.